Evaluation of X-MAN Standard for EGFR Genotyping Assay

Mutations in the epidermal growth factor receptor (EGFR) gene correlate with the effectiveness of therapy for the treatment of advanced non‐small cell lung cancer (NSCLC). Patients with an EGFR mutation respond more favourably to tyrosine kinase inhibitor therapy, therefore knowledge of their mutation status will aid in developing an effective first‐line course of treatment. In this application note, Horizon’s X-MAN™ genomic DNA Standard was used in the company’s routine EGFR assay to evaluate how efficiently it detects the exon 19 deletion.